On April 22, AstraZeneca announced that the China National Medical Products Administration officially approved Capisetid (generic name: Capisetid tablets) combined with Fulvestrant on April 15, 2025 for the treatment of adult patients with locally advanced or metastatic breast cancer who have progressed after at least one endocrine therapy in the metastatic stage, or relapsed during adjuvant therapy or within 12 months after completion of adjuvant therapy, who are hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, and have one or more PIK3CA/AKT1/PTEN changes.